Akari Therapeutics
AKTX | NASDAQ
$8.24
+$0.24 (+3.00%)
At close: Oct 30, 2026, 4:00 PM ET
$8.07
-$0.17 (-2.10%)
Pre-market:
Nov 2, 2026, 7:28 AM ET
Market Data
Market Cap $18.92M
Enterprise Value $11.92M
Beta 1.44
Average Volume 65.71K
Shares Outstanding (Diluted) 1.79M
Shares Change YoY 11285.24%
Institutional Ownership 8.37%
Exchange NASDAQ
ISIN US00972G4055
Price Performance
Price Change 1M -11.4%
Price Change 3M 4.8%
Price Change 6M 50.6%
Price Change YTD -28.7%
Price Change 1Y -72.5%
Price Change 3Y -94.0%
Price Change 5Y -99.4%
1M CAGR (ann.) -10.0%
1Y CAGR (ann.) -72.5%
5Y CAGR (ann.) -63.9%
All-Time CAGR -49.2%
Valuation
PE Ratio -0.01
Forward PE N/A
PEG Ratio 0.00
Forward PEG -0.00
PS Ratio N/A
Forward PS N/A
PB Ratio 1.02
P/FCF Ratio -1.76
P/Adj. FCF Ratio -1.46
P/OCF Ratio -1.38
EV/Sales N/A
EV/EBIT -0.37
EV/EBITDA -0.37
EV/FCF -1.11
Earnings Yield -19417.5%
FCF Yield -56.8%
Adj. FCF Yield -68.4%
Financial Health
Net Cash $7M
Total Debt $693K
Cash & Short-Term Investments $7.69M
Total Assets $38.62M
Current Ratio 0.60
Quick Ratio 0.60
Debt / Equity Ratio 0.04
Debt / EBITDA -0.02
Debt / FCF -0.06
OCF / Debt -15.49
Interest Coverage -31.49
Altman Z-Score -12.62
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -20.5%
Returns
Return on Assets -80.2%
Return on Equity -147.4%
Return on Invested Capital -115.2%
Return on Capital Employed -125.5%
Return on Tangible Assets -371.9%
Historical Growth (CAGR)
Revenue CAGR 3Y N/A
Revenue CAGR 5Y N/A
Revenue CAGR 10Y N/A
EPS CAGR 3Y 76.8%
EPS CAGR 5Y 50.0%
EPS CAGR 10Y 32.3%
FCF CAGR 3Y 21.3%
FCF CAGR 5Y 14.9%
FCF CAGR 10Y 10.7%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 2
EPS Growth Next 3Y 33.3%
Revenue Growth Next 3Y N/A
Earnings Date Dec 4, 2026
EPS Estimate (next Q) -$2.23
EPS Growth Est (next Q) -44.1%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $24.75
Price Target Upside 200.4%
Cash Flow
Operating Cash Flow $-10.74M
Free Cash Flow $-10.74M
Adj. Free Cash Flow $-12.94M
FCF Per Share -$5.99
OCF Per Share -$5.99
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $0
Operating Income $-30.99M
EBITDA $-31.84M
Net Income $-30.96M
EPS (Diluted) -$1,600.00
Revenue / Employee N/A
Profit / Employee $-5.16M
Employees 6
Add to Watchlist
Select watchlists to add or remove AKTX